Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients
NCT02949154 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65
Last updated 2024-05-06
Summary
A retrospective study investigating the relationship between FDG-PET uptake and LDH levels.
Conditions
Sponsors & Collaborators
-
University Medical Center Groningen
lead OTHER
Principal Investigators
-
M. Jalving, MD, PhD · University Medical Center Groningen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-30
- Primary Completion
- 2017-04-30
- Completion
- 2017-04-30
Countries
- Netherlands
Study Locations
More Related Trials
-
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
NCT04464590 ·Status: COMPLETED
-
Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
NCT00200668 ·Status: TERMINATED ·Phase: NA
-
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592 ·Status: TERMINATED ·Phase: PHASE1
-
Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
NCT04253574 ·Status: COMPLETED
-
FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer
NCT02995902 ·Status: COMPLETED ·Phase: NA
-
PD-L1 PET Imaging in Melanoma Patients
NCT03520634 ·Status: COMPLETED ·Phase: NA
-
F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response
NCT00180193 ·Status: TERMINATED
-
Early Versus Late FDG-PET/CT in Bladder Cancer
NCT03065725 ·Status: COMPLETED
-
Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations
NCT02858167 ·Status: COMPLETED ·Phase: NA
-
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
NCT03525665 ·Status: COMPLETED
-
Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma
NCT00775957 ·Status: TERMINATED
-
Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT
NCT00534989 ·Status: COMPLETED ·Phase: NA
-
Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET
NCT00180245 ·Status: COMPLETED
-
18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions
NCT04306484 ·Status: COMPLETED
-
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide
NCT03065790 ·Status: TERMINATED
-
MPDL3280A-treatment-IST-UMCG
NCT02478099 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images
NCT01109953 ·Status: TERMINATED
-
Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas
NCT02585219 ·Status: UNKNOWN
-
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
NCT03132090 ·Status: UNKNOWN ·Phase: NA
-
18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.
NCT02969564 ·Status: COMPLETED
-
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role
NCT04333524 ·Status: ACTIVE_NOT_RECRUITING
-
Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
NCT06055764 ·Status: NOT_YET_RECRUITING
-
PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma
NCT00943423 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
PET Response During Chemoradiation of Lung Cancer
NCT02315053 ·Status: COMPLETED ·Phase: NA
-
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy
NCT03888950 ·Status: RECRUITING ·Phase: NA